This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Galhenage SP, Sanders GD, Patel K, Schulman KA, McHutchison JG.Modeling the potential cost-effectiveness of adding a novel stat-C agent to current standard therapy in patients with genotype 1 chronic hepatitis C infection. Hepatology 46 (Suppl. 1): 859-860 abstr. 1396, No. 4, Oct 2007
Rights and permissions
About this article
Cite this article
STAT-C + standard therapy cost effective in hep C. Pharmacoecon. Outcomes News 542, 4 (2007). https://doi.org/10.2165/00151234-200705420-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705420-00007